A randomized, double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 5, 2013, Pages 483-486

  Rockstroh, Jürgen K ^a   Dejesus, Edwin ^b   Henry, Keith ^c   Molina, Jean Michel ^d   Gathe, Joseph ^e   Ramanathan, Srinivasan ^f   Wei, Xuelian ^f   Plummer, Andrew ^f   Abram, Michael ^f   Cheng, Andrew K ^f   Fordyce, Marshall W ^f   Szwarcberg, Javier ^f  

^a UNIVERSITY OF BONN   (Germany)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d Hopital Saint Louis   (France)

^e Therapeutic Concepts   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

Antiretroviral therapy; Cobicistat; Efavirenz; Elvitegravir; Emtricitabine; HIV; Tenofovir; Treatment naive

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE JAUNDICE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LENTIVIRINAE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BONE DENSITY; CARBAMATES; CONFIDENCE INTERVALS; CREATININE; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PYRIDINES; QUINOLONES; RITONAVIR; RNA, VIRAL; THIAZOLES; TRIGLYCERIDES;

EID: 84876409173     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318286415c     Document Type: Article

References (11)

1. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379:2439-2448.
2. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379:2429-2438.
3. US Department of Health and Human Services. Panel on Antiretroviral Guidelines for adults and Adolescents Recommends a fixed-dose combination product of elvitegravir/cobicistat/tenofovir/emtricitabine as an alternative regimen in antiretroviral treatment-naive individuals with HIV-1 infection. Available at: http://www.aidsinfo.nih.gov/contentfiles/AdultARVStatementOnEVG- COBI-TDF-FTC.pdf. Accessed September 24, 2012.
4. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61:32-40.
5. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.
6. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39-48.
7. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378:229-237.
8. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378:238-246.
9. Daar ES, Tierney C, Fischl M, et al. ACTG 5202: final results of abacavir/lamivudine (ABC/3TC) or tenofovir DF/emtricitabine (TDF/FTC) with either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in treatmentnaive HIV-infected patients [Abstract]. In:17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010; San Francisco, CA.
10. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir- based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
11. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed Feb 15, 2013.